{"entity":{"id":"neomorph","kind":"company","name":"Neomorph","aka":[],"tldr":"Neomorph makes small molecules called molecular glues that stick a disease protein to the cell's disposal machinery so it is destroyed. Its first drug is in an early trial for clear cell kidney cancer.","summary":"Neomorph is a San Diego company that engineers neomorphic protein surfaces to discover molecular glue degraders, claiming the largest proprietary molecular glue target space with multiple newly identified degrons, glue libraries and a broad portfolio of E3 ubiquitin ligases. Its lead programme, NEO-811, degrades ARNT (HIF-1 beta) and is in a first-in-human phase 1/2 monotherapy trial in advanced clear cell renal cell carcinoma; two undisclosed solid tumour programmes and early oncology, immunology, neurology and cardiometabolic targets follow. Partnerships include an option-to-license deal with AbbVie in oncology and immunology (January 2025, up to 1.64 billion US dollars), a multi-target collaboration with Biogen, and work with Novo Nordisk. Neomorph closed a 100 million US dollar Series B in April 2026 led by Deerfield Management.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://neomorph.com/"},{"label":"Pipeline","url":"https://neomorph.com/pipeline/"},{"label":"Series B press release","url":"https://neomorph.com/press-release/neomorph-announces-closing-of-100-million-series-b-financing/"},{"label":"AbbVie collaboration","url":"https://neomorph.com/press-release/abbvie-and-neomorph-announce-collaboration-to-develop-molecularglue-degraders-for-oncology-and-immunology/"}],"tags":[],"related":[],"cancers":["rcc"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series A and founding year not sourced; no SEC Form D filings were found under the company name. NEO-811's target (ARNT/HIF-1 beta) has no id in the target list."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://neomorph.com/","stage":"startup","investors":["deerfield-management","longwood-fund","alexandria-venture-investments"],"funding":[{"round":"Series B","year":2026,"amountUsd":100000000,"source":"https://neomorph.com/press-release/neomorph-announces-closing-of-100-million-series-b-financing/","note":"Led by founding investor Deerfield Management; closed April 2026"}]},"route":"/companies/neomorph/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"company":[{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/"},{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/"},{"id":"longwood-fund","kind":"company","name":"Longwood Fund","route":"/companies/longwood-fund/"}]}}